Key result
Prior oral antithrombotic therapy was independently associated with a significantly increased risk of early death within 14 days (HR 2.01) in patients with supratentorial intracerebral hemorrhage.
Why the study?
Does prior oral antithrombotic therapy increase the risk of early death in patients with supratentorial intracerebral hemorrhage?
Cohort (n=389)
No
Does prior oral antithrombotic therapy increase the risk of early death in patients with supratentorial intracerebral hemorrhage?
Hazard Ratio: 2.01 (95% CI 1.11–3.65)
Absolute Event Rate: 28% vs 8.1%
p-value: p=0.022
Prior oral antithrombotic therapy is independently associated with a twofold increased risk of early death in patients presenting with supratentorial intracerebral hemorrhage.
Urges caution with OAT history in supratentorial ICH; hypothesis-generating and requires prospective confirmation.
BACKGROUND AND PURPOSE: Although oral antithrombotic therapy (OAT) is a risk factor of intracerebral hemorrhage (ICH), the clinical course of supratentorial ICH with prior OAT is unclear. We therefore assessed the characteristics of supratentorial ICH with OAT to determine whether OAT is independently associated with early death in supratentorial ICH. METHOD: We retrospectively enrolled consecutive patients with supratentorial ICH admitted to the Stroke Center of Kawasaki Medical School Hospital within 24 hours of onset, from April 2004 to March 2009. The group with OAT therapy (OA group) was compared with the group without (non-OA group). RESULTS: A total of 389 patients with supratentorial ICH (median age 68 years, 61% males) were enrolled in the present study. OAT was used in 24% of patients. The OA group was older than the non-OA group (median 74 vs. 66 years, p<0.001). In the OA group, Glasgow Coma Scale was less (10 vs. 13, p<0.001), and hematomas were larger (22 mL vs. 14 mL, p<0.001). Early death was more frequently observed in the OA group than in the non-OA group (28% vs. 8.1%, p<0.001). Unadjusted HR of OAT for death within 14 days was 3.62 (95% CI: 2.06-6.33, p<0.001), the age- and sex-adjusted HR was 3.84 (95% CI: 2.12-6.96, p<0.001), and HR adjusted for age, sex, GCS, and hematoma volume was 2.01 (95% CI: 1.11-3.65, p=0.022). HR adjusted for age, sex, GCS, and hematoma volume at day 1 was 2.63 (p=0.34), day 3: 2.35 (p=0.03), day 7: 2.01 (p=0.04), and day 14: 1.90 (p=0.04). CONCLUSION: The OA group patients were older, their GCS was lower, they had larger hematoma volume, and more frequent occurrence of early death. Prior oral antithrombotic therapy is associated with early death in patients with supratentorial ICH.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2011) conducted a cohort in Supratentorial intracerebral hemorrhage (n=389). Prior oral antithrombotic therapy vs. No prior oral antithrombotic therapy was evaluated on Early death (within 14 days) (HR 2.01, 95% CI 1.11-3.65, p=0.022). Prior oral antithrombotic therapy was independently associated with a significantly increased risk of early death within 14 days (HR 2.01) in patients with supratentorial intracerebral hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: